Sonova FY 2025-26 profit beats estimates despite China headwinds

Sonova delivered a modest FY2025-26 beat, with normalized EBITA of CHF 811.2 million versus CHF 780.8 million consensus and margin of 22.5% versus 21.6%, while sales matched expectations at CHF 3.61 billion. Results were mixed beneath the headline: hearing instruments outperformed, but cochlear implants lagged sharply, especially in China, and reported EBITA was pressured by FX. Management guided FY2026-27 for 5-8% sales growth and 7-10% core EBIT growth at constant currencies, and lifted the dividend 7% to CHF 4.70 per share.

Analysis

The cleanest read-through is not the headline beat, but the quality of the beat: margin expansion came from mix and operating discipline, while FX masked the underlying earnings power. That matters because hearing-aid demand is relatively non-cyclical, so the market is likely to re-rate the stock on sustainable margin resilience rather than top-line growth. The next leg higher depends on whether management can keep hearing instruments compounding at mid-single digits while extracting enough cost out of the divestiture to offset the drag from the consumer exit.

The weak cochlear implant franchise is the bigger strategic issue. China VBP is not a one-quarter noise event; it is a structural pricing and channel-reset risk that can spill into adjacent medtech categories if reimbursement authorities view the playbook as successful. Competitively, this creates room for lower-cost regional implant players and may force global incumbents to trade margin for share, especially in APAC over the next 2-4 quarters.

The balance sheet and dividend signal confidence, but the cash return also narrows strategic flexibility if the implant business stays under pressure. A stronger CHF would be a second-order headwind because guidance is explicitly FX-sensitive, so the stock’s near-term setup is less about operating execution and more about whether currency and China become estimate-cutting items. The market is likely underestimating how much of next year’s upside is already pre-committed to FX neutrality assumptions.

Contrarian take: the consumer hearing divestiture may be a hidden catalyst rather than a drag. Removing a structurally weaker, lower-multiple asset should lift group quality and make the remaining business screen more like a defensible premium medtech compounder, which could matter more than the headline EPS optics once the separation is clearer. The risk is that investors over-focus on the reported EPS dilution from discontinued ops and miss the potential multiple expansion on a cleaner story.

Key Decisions for Investors

• Long SONVY on any post-earnings pullback over the next 1-3 weeks; target a re-rating toward premium medtech peers if the market starts valuing the cleaner hearing-aids franchise, with downside anchored by recurring demand and net debt improvement.
• Buy SONVY calls or call spreads for the next 3-6 months if you expect the consumer divestiture process to simplify the equity story; risk/reward improves if management gives more detail on separation timing and use of proceeds.
• Short a basket of exposed China medtech / implant names against SONVY over 1-2 quarters; the VBP issue looks like a pricing-template risk that can spread beyond this company and pressure margins across the group.
• If maintaining a long SONVY position, hedge CHF strength with currency exposure or reduce size on rallies; guidance sensitivity to FX creates a 1-2 point sales and 3-4 point EBIT headwind at current rates.
• Avoid chasing cochlear implant suppliers until there is evidence of stabilization in China reimbursement volumes; the risk/reward remains asymmetrically negative for the next 2-4 quarters.